BioCentury
ARTICLE | Financial News

Shanghai Henlius up for Hong Kong IPO

December 15, 2018 12:06 AM UTC

Biosimilars company Shanghai Henlius Biotech Inc. (Shanghai, China) proposed on Friday to list on the Hong Kong stock exchange.

Shanghai Henlius' lead compound is HLX01, a biosimilar of cancer and autoimmune drug MabThera rituximab from Roche (SIX:ROG; OTCQX:RHHBY). China's National Medical Products Administration (NMPA) is reviewing an NDA for the drug under Priority Review to treat non-Hodgkin lymphoma; Henlius expects a decision this year or early next...